Antares Pharma

Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2021 Results - Earnings Call Transcript

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Meets Q1 Earnings Estimates

EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

Increased Revenue 27% Year-Over-Year to $42.1 Million

Antares Pharma Reports First Quarter 2021 Financial and Operating Results

EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society (PES) 2021 Virtual Annual Meeting on April 30 – May 3, 2021.

Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.

Antares Pharma to Report First Quarter 2021 Financial and Operating Results

Antares Pharma operates in crowded markets with relatively low barriers to entry and intense competition. Their flagship product, XYOSTED, grew significantly in 2019 and 2020 but competitors may enter the market as soon as October 2021.

Antares Pharma - Why It's A $4 Stock (And Might Remain So)

EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the Company's proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs.

Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer

Antares Pharma's (ATRS) CEO Bob Apple on Q4 2020 Results - Earnings Call Transcript

Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Q4 Earnings Lag Estimates

Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the estimate of $0.03.

Recap: Antares Pharma Q4 Earnings

EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present and host investor meetings at the Raymond James 42nd Annual Virtual Institutional Investors Conference and the Cowen 41st Annual Virtual Healthcare Conference.

Antares Pharma to Present at Two Upcoming Investor Conferences

EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the market opens.

Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results

EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference being held on February 22-26, 2021.

Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference

Fluent Inc

OPKO Health

These interesting low-cost stocks have the opportunity to grow.

3 Top Stocks Trading Under $5 a Share

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020.

Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer is scheduled to present at the Jefferies Virtual London Healthcare Conference.

Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial and operating results on Thursday, November 5, 2020, before the market opens.

Antares Pharma to Report Third Quarter 2020 Financial and Operating Results

Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.

Antares Is Finally Having A Long Overdue Upward Move

Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization

Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.

EWING, N.J., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference.

Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs

Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript

News for Antares Pharma Stock (ATRS)